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LungCowpox virus infection induces interleukin-10 (IL-10) production from mouse bone marrow-derived
dendritic cells (BMDCs) or cells of the mouse macrophage line (RAW264.7) at about 1800 pg/ml, whereas
infections with vaccinia virus (strains WR or MVA) induced much less IL-10. Similarly, in vivo, IL-10 levels in
bronchoalveolar lavage ﬂuids of mice infected with cowpox virus were signiﬁcantly higher than those after
vaccinia virus infection. However, after intranasal cowpox virus infection, although dendritic and T-cell
accumulations in the lungs of IL-10 deﬁcient mice were greater than those in wild-type mice, weight-loss and
viral burdens were not signiﬁcantly different. IL-10 deﬁcient mice were more susceptible than wild-type mice
to re-infection with cowpox virus even though titers of neutralizing antibodies and virus-speciﬁc CD8 T cells
were similar between IL-10 deﬁcient and wild-type mice. Greater bronchopneumonia in IL-10 deﬁcient mice
than wild-type mice suggests that IL-10 contributes to the suppression of immunopathology in the lungs.enetics andMicrobiology, Box
0, USA. Fax: +1 919 684 8735.
l rights reserved.© 2011 Elsevier Inc. All rights reserved.Introduction
IL-10 was ﬁrst described as a CSIF (cytokine synthesis inhibitory
factor), a cytokine produced by T-helper 2 (Th2) cells that inhibited
the production of cytokines by Th1 cells (Fiorentino et al., 1989). It is
now known to be produced by cells of numerous types, including B
cells (Burdin et al., 1997; O'Garra et al., 2004), macrophages, dendritic
cells (Boonstra et al., 2006), mast cells (Ishizuka et al., 1999), and
eosinophils (Nakajima et al., 1996), as well as various T cells including
CD8 and CD4 T cells (reviewed by Hawrylowicz and O'Garra, 2005;
O'Garra et al., 2008; O'Garra and Vieira, 2007).
The primary role of IL-10 is to act as a key regulator of immunity to
infection (reviewed by Couper et al., 2008). IL-10 is an immunosup-
pressive cytokine that inhibits multiple macrophage and DC functions,
including: their synthesis of proinﬂammatory cytokines; expression
of costimulatory molecules and MHC class II proteins; antigen
presentation; and DC trafﬁcking (reviewed by Couper et al., 2008;
Grutz, 2005; O'Garra et al., 2008). In a normal course of events, IL-10
can act to curtail inﬂammatory and adaptive immune responses that
otherwise might be damaging to the host. Indeed, IL-10 is one of theprincipal active agents of regulatory T cells (Li and Flavell, 2008;
Roncarolo et al., 2006) and regulatory B cells (Mauri and Ehrenstein,
2008).
In its role as a key regulatory cytokine, IL-10 is a crucial factor in
the outcome of several viral diseases (reviewed by Blackburn and
Wherry, 2007; Filippi and von Herrath, 2008). A number of viruses
including lymphocytic choriomeningitis virus (Brooks et al., 2008,
2010), hepatitis C virus (Brady et al., 2003; Saito et al., 2008), hepatitis
B virus (Hyodo et al., 2004), murine gammaherpesvirus 68 (Siegel
et al., 2008), and HIV (Contreras et al., 2004; Gee et al., 2006, 2007;
Granelli-Piperno et al., 2004; Gupta et al., 2008) induce elevated levels
of IL-10 production during infection which correlate with the
impairment of T-cell responses and the failure to control viral
replication. Herpes simplex virus can stimulate infected T cells to
selectively synthesize IL-10, and elevated levels of IL-10 have also
been found in T cells of mice during acute infections with Sin Nombre
virus (Schountz et al., 2007; Sloan and Jerome, 2007).
Underscoring the importance of IL-10 in viral infections, several
herpes- and poxviruses, including Epstein–Barr virus (Hsu et al., 1990;
MacNeil et al., 1990), human cytomegalovirus (Jenkins et al., 2008;
Kotenko et al., 2000; Lockridge et al., 2000), orf virus (Fleming et al.,
2000, 1997), lumpy skin disease virus (Tulman et al., 2001), and Yaba-
like disease virus (Bartlett et al., 2004), encode viral proteins that are
homologues of IL-10 or the IL-10-like family members IL-19, IL-20,
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from those of the host IL-10, and the biological roles of each viral IL-10
are not completely understood. Nonetheless these viral proteins are
thought to mimic actions of IL-10 to promote viral replication and
contribute to the pathogenic properties of each virus.
Interestingly, although the viruses of the orthopoxvirus genus
have acquired numerous homologues of host genes (reviewed by
Hughes et al., 2010), including several genes encoding proteins that
inhibit or modify host immune responses, none of these viruses is
known to encode a viral homologue of IL-10. The orthopoxviruses
may have failed to acquire genes encoding IL-10 homologues because
they fail to derive beneﬁt from such homologues. In this regard,
available information has been equivocal. On the one hand, vaccinia
virus-vectored expression of mouse IL-10 in immunocompetent
C57BL/6 mice did result in both the suppression of natural killer cell
activity at 3 days post-infection, and reduced (25–50%) virus-speciﬁc
CTL activity at 6–7 days post-infection in comparison to infectionwith
control vaccinia virus. On the other hand, infections of BALB/cmice, by
either dermal scariﬁcation, intraperitoneal, intranasal, or intracerebral
inoculation, with recombinant vaccinia viruses expressing mouse IL-
10 did not differ signiﬁcantly from infections with wild-type vaccinia
viruses in any of the following: visible lesions; viral load in the lungs;
morbidity; mortality; protective immunity to a 100-fold lethal
challenge with vaccinia virus; or vaccinia virus-speciﬁc antibody
response (Kurilla et al., 1993).
An alternative explanation for the orthopoxviruses' failure to
encode homologues of IL-10 is that some of these viruses may have
acquired the capacity to use the host-encoded IL-10 to their
advantage. The ﬁrst evidence of this was provided by Slezak et al.
(2000) who showed that vaccinia virus infection of humanmonocytes
resulted in a modest induction of IL-10 (46 pg/ml) by 24 hr post-
infection. Subsequently, Maloney et al. (2005) showed that at least
one orthopoxvirus proteinmight affect IL-10 expression under certain
circumstances, in that the vaccinia virus protein A52R can strongly
enhance lipopolysaccharide-induced IL-10 production in cultured
RAW264.7 cells. Liu et al. (2005) found that vaccinia virus infection of
primary human keratinocytes resulted in increased expression of
immunoregulatory cytokines including IL-10 (30 pg/ml). However,
the viral induction of IL-10 was cell-type speciﬁc, insofar as there was
no induction of IL-10 by vaccinia virus infection of dermal microvas-
cular endothelial cells, or XS52 cells, a line of cells established from
mouse epidermis-derived dendritic cells (Deng et al., 2006). Intrigu-CP
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Fig. 1. Cowpox virus induces higher amounts of IL-10 in cultured cells than vaccinia viruses W
(CPXV), VV-WR, or MVA. Mouse BMDCs were infected with 10 PFU/cell, or an amount of U
infected with media alone or media containing Pam/CpG, as negative and positive controls fo
IL-10 culture supernatants with the BioPlex system according to themanufacturer's protocol.
BMDCs after infection with cowpox virus in the absence or presence of 40 μg/ml cytosine arab
RAW264.7 cells after infection with CPXV, VV-WR, or MVA. RAW264.7 cells were infected w
After 6 hr, the culture media were harvested and the levels of IL-10 determined with a BDingly, studies of the effects of cowpox virus infection of BALB/c mice
(Erwin, Hutt, and Lyons, personal communication), as well as studies
of Knorr et al. (2006) and Smee et al. (2008) with vaccinia and
cowpox viruses, showed that while both viruses could induce
elevated levels of IL-10 in serum and lung tissue, cowpox virus
induced IL-10 accumulations could be up to 40-fold greater than those
induced by vaccinia virus.
Collectively, these results suggested that cowpox virus, which
possesses many more accessory genes than vaccinia virus, might have
a special capacity to induce IL-10 as part of its strategy to suppress
host immune responses. The objectives of this study were to
determine the effects of cowpox virus infection on host IL-10, and
to determine the effects of IL-10 on cowpox virus replication in vivo.
Results
Cowpox virus induces secretion of IL-10 from mouse bone marrow
derived dendritic cells
To determine if cowpox virus can induce the production of IL-10 in
host cells, cultures of mouse bone marrow-derived dendritic cells
(BMDC) were infected with cowpox virus, and cytometric bead arrays
were used to measure the accumulation of IL-10 in the cell culture
medium. As shown in Fig. 1A, cowpox virus induced high levels of IL-
10 (~1760 pg/ml) by 24 hr after infection. Control cultures of BMDCs
were treated with a mixture of Pam3CSK4 and ODN 1826, (an
unmethylated oligonucleotide with CpG motifs), here collectively
referred to as Pam/CpG, to stimulate Toll-like receptors (TLRs) 2 and 9
respectively. Pam/CpG treatment of the BMDCs produced a modest
but measurable induction of IL-10, consistent with that of previous
studies (Samarasinghe et al., 2006).
To determinewhether infectionwith other orthopoxviruses would
similarly induce the production of IL-10 in host cells, additional
cultures of mouse BMDCs were infected with vaccinia virus strain WR
(VV-WR), or the highly attenuated strain of vaccinia virus, modiﬁed
vaccinia Ankara (MVA), and the production of IL-10 in the cell culture
media was measured by cytometric bead array 24 hr after infection.
As shown in Fig. 1A, only cowpox virus, and neither VV-WR nor MVA
was able to induce the production of IL-10 by BMDCs. To determine
whether active infection was required for IL-10 induction, parallel
cultures of BMDCs were treated with either UV- or heat-inactivated
viruses. The inactivated viruses did not induce detectable IL-10CP
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Fig. 2. Cowpox virus induces higher amounts of IL-10 in the lungs of infected mice than
vaccinia viruses WR or MVA. (A) C57BL/6NCrl mice (8–10 week old female mice) were
infected intranasally with 104 PFU of CPXV, VV, or MVA, or mock infected with PBS. BAL
ﬂuid was collected 6 days after infection. The levels of IL-10 in the BAL ﬂuids were
determined by cytometric bead array (Bio-Rad). Bars represent the SEM. For infections
with CPXV, VV and MVA, n=10; for PBS, n=5. Values of p were calculated by two-
tailed Student's t test: CPXV versus VV-WR p=0.0189; CPXV versus MVA p=0.0006.
Dashed line indicates the minimum level of detection of IL-10. (B) Viral load in the
lungs of mice infected with similar, sublethal doses of CPXV, VV or MVA. C57BL/6NCrl
mice (8–10 week old female mice) were infected intranasally with 104 PFU of virus. For
all groups, n=3. Mice were euthanized 6 days after infection, and the titers in the lungs
were determined by plaque assay (CPXV and VV-WR) or immunostaining (MVA).
Differences in the means among groups were tested by two-tailed Student's t test
indicating no signiﬁcant difference (p=0.72) in lung titers of CPXV and VV-WR-
infected mice.
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entry into the cell, or some products of viral replication, but not simply
inactivated virus particles, are required to stimulate IL-10 induction.
IL-10 induction was stimulated by cowpox virus infection in the
presence or absence of cytosine arabinoside, an inhibitor of viral DNA
replication, showing that events during the early phase of virus
replication are sufﬁcient to induce the observed IL-10 accumulation
(Fig. 1B).
Cowpox virus induces IL-10 in mouse macrophage-derived RAW264.7
cells
To determine whether cowpox virus-speciﬁc induction of IL-10
could be reproduced in cells other than primary BMDCs, cells of a
mouse macrophage cell line (RAW264.7 cells) were infected with
cowpox, VV-WR, MVA, or mock infected with media alone. A parallel
culture of cells was treated with LPS as a positive control for IL-10
induction. RAW264.7 cells were used both because they are derived
from mouse macrophages, which together with dendritic cells are an
important source of cytokines early after infection in the mouse
(reviewed by Lohmann-Matthes et al., 1994; Peters-Golden, 2004),
and because RAW264.7 cells are known to produce IL-10 in response
to LPS treatment (Hasko et al., 1996). The levels of IL-10 in the culture
media were determined 6 hr after infection. As shown in Fig. 1C,
RAW264.7 cells infectedwith cowpox virus produced high amounts of
IL-10 (~1800 pg/ml), whereas cells infected with either VV-WR or
MVA produced much lower levels (~80 and 100 pg/ml respectively),
consistent with earlier determinations of IL-10 induction by vaccinia
viruses in cultured cells (Liu et al., 2005; Slezak et al., 2000). As
expected, control cultures treated with LPS also produced high levels
of IL-10 (~2000 pg/ml), whereas IL-10 accumulation above back-
ground levels was not detected in the culture media from untreated
RAW264.7 cells.
In summary, the preceding results showed that cowpox virus
induced signiﬁcant levels of IL-10 production from primary BMDC and
macrophage-derived RAW264.7 cells, while VV-WR andMVA did not.
The induction of IL-10 by cowpox virus required viral replication, but
neither viral DNA replication nor viral late replication, which suggests
that either viral entry, or products of early viral replication are
sufﬁcient to trigger IL-10 induction.
Cowpox virus induces more IL-10 in vivo than vaccinia virus
To determine whether cowpox virus induced more IL-10 in vivo
than the less virulent vaccinia virus, the bronchoalveolar lavage ﬂuid
(BAL) was collected from infected mice and assayed for IL-10. For this
purpose, cohorts of C57BL/6 mice (n=10 per group) were infected
intranasally with 104 PFU of either cowpox virus, VV-WR, or MVA.
Five control animals were mock-infected with diluent alone, and BAL
ﬂuid harvested in parallel with the virus-infected experimental
groups. Mice were sacriﬁced on the sixth day after challenge. As
shown in Fig. 2A, cowpox virus induced signiﬁcantly higher levels of
IL-10 in the BAL ﬂuid than those induced by the corresponding dose of
VV-WR. MVA did not induce levels of IL-10 above those present in
mock-infected mice. Comparison of virus titers in the lungs of mice
infected with cowpox virus or VV-WR indicated that there was no
statistically signiﬁcant difference in viral load in mice infected with
these two viruses. As expected, infectious MVA was not detectable in
the lungs (Fig. 2B).
Weight loss and viral burdens are not signiﬁcantly different in wild-type
and IL-10 deﬁcient mice after sublethal cowpox virus infection
To begin to determine whether IL-10 induction contributed to the
pathogenicity of cowpox virus, the effects of sub-lethal cowpox virus
infections of mice genetically deﬁcient in IL-10 were compared to theeffects of infection of wild-type control animals. As shown in Fig. 3A,
after intranasal infection with a sublethal dose of virus (104
PFU/mouse), the course of disease in IL-10 deﬁcient mice was very
similar to the course of disease in wild-type mice, with all animals
surviving virus challenge, and no statistically signiﬁcant difference in
the weight losses between the groups. Consistent with this result,
additional cohorts of wild-type and IL-10 deﬁcient mice (n=5 mice
per group per timepoint) challenged with cowpox virus contained
similar viral loads in the lungs (Fig. 3B). Taken together, these results
showed that IL-10 deﬁcient mice were not signiﬁcantly more sensitive
or resistant than wild-type mice to primary challenge with a sublethal
dose of cowpox virus. Similarly, IL-10 deﬁcient mice were not signiﬁ-
cantly different fromwild-typemice in their responses to infectionwith
cowpox virus at a 10-fold higher dose, which resulted in 20% weight
loss within 5 days of infection (Fig. 3C), at which time the mice were
euthanized.IL-10 suppresses DC and T-cell accumulation in the lungs of mice
intranasally infected with sublethal doses of cowpox virus
Although neither weight loss nor viral load following sublethal
infection with cowpox virus was affected by the absence of IL-10,
examination of the inﬂammatory response in the lungs of infected
mice revealed marked differences between wild-type and IL-10
deﬁcient mice. In the late stages of infection (days 14–21), there
were greater numbers of dendritic cells CD4, and CD8 T cells in the
lungs of IL-10 deﬁcient mice as compared with wild-type mice
(Figs. 4A–C). In addition, histological analyses of lungs of mice at
14 days after infection showed that wild-type and IL-10 deﬁcientmice
(Figs. 4D and E) had predominantly mononuclear cellular inﬁltrates
that were consistent with the increased cellularity determined by
ﬂow cytometry. In both wild-type and IL-10 deﬁcient mice, the
inﬁltrates were greatest around the subsegmental pulmonary arteries
and associated bronchioles, becomingmore diffuse in the surrounding
tissue. In many cases, the lesions were larger in the lungs of IL-10
deﬁcient mice than in those of wild-type mice suggesting a greater
degree of pulmonary inﬂammation in the absence of IL-10.
These results indicate that both the magnitude and the duration of
the inﬂammatory responses to viral infection are increased in the
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mice.
IL-10 deﬁcient mice are more susceptible than wild-type mice to
re-infection with cowpox virus
To determine whether wild-type and IL-10 deﬁcient mice were
similarly protected from re-challenge with a lethal dose of cowpox
virus, groups of mice were infected intranasally with cowpox virus
(104 PFU per mouse), and then challenged with a lethal dose (106 PFU
per mouse) 10 weeks after the primary infection. As expected, all
wild-type mice were protected from re-challenge, with mice exhibit-
ing no weight loss or other signs of morbidity (Fig. 5A). The IL-10
deﬁcient mice were also protected from re-challenge, but unlike wild-
type mice they exhibited a transient weight loss of up to about 10%
(Fig. 5A) although all IL-10 deﬁcient mice did survive. At a 10-fold
higher challenge dose (107 PFU per mouse) all wild-type mice were
protected from re-challenge, with mice exhibiting transient weight
loss of up to about 8%, but all IL-10 deﬁcient mice lost weight rapidly,
and had to be euthanized on the 7th day after challenge (Fig. 5A).
These results suggested that IL-10was required for optimal protection
against re-infection, especially at higher rechallenge doses.
One of the major correlates of protection against poxvirus
infection is the development of virus neutralizing antibodies
(Panchanathan et al., 2006, 2010). To begin to determine the basis
for the enhanced susceptibility of IL-10 deﬁcient mice to rechallenge,
the production of serum antibody against cowpox virus in wild-type
and IL-10 deﬁcient mice was compared. As shown in Fig. 5B, sera
collected at multiple timepoints after primary infection (from thesame cohort of animals shown in Figs. 3–4) were assayed by ELISA for
binding activity against the cowpox virus B5 protein. The cowpox
virus B5 protein is expressed on the outer membrane of the
extracellular enveloped virion (EV), and antibodies against B5 have
been shown to limit dissemination of poxviruses in vivo (Benhnia et
al., 2009; Galmiche et al., 1999; Law and Smith, 2001). As shown in
Fig. 5B, anti-B5 titers of wild-type and IL-10 deﬁcient mice were
similar at all timepoints analyzed. Titers in IL-10 deﬁcient mice were
slightly lower than titers in wild-type mice, but because the antibody
levels present in both wild-type and IL-10 deﬁcient mice were at or
above the levels that are predictive of protection (Barefoot et al.,
2008) the difference is unlikely to be biologically signiﬁcant. Similarly,
analyses of the same sera for neutralizing activities against cowpox
virus showed that sera from both groups of mice neutralized live
cowpox virus equally well (Fig. 5C). Taken together, these results
suggest that protective anti-cowpox virus humoral responses were
intact in wild-type and IL-10 deﬁcientmice, and that the susceptibility
of IL-10 deﬁcient mice to rechallenge cannot be attributed to failure of
the humoral immune response in those animals.
To determine whether cellular responses were intact in IL-10
deﬁcient mice, the production of cowpox virus-speciﬁc CD8 T cells in
wild-type and IL-10 deﬁcient mice was analyzed. Using cells from the
same cohort of mice as in Figs. 3–4, an MHC Class I tetramer was used
to identify Kb-restricted CD8 T cells recognizing the immunodomi-
nant epitope (TSYKFESV) of the cowpox virus B8 protein. As shown in
Fig. 5D, wild-type and IL-10 deﬁcient mice had similar levels of anti-
B8 T cells in the spleen at all timepoints tested. This result suggested
that primary CD8 T cell responses were intact in IL-10 deﬁcient mice,
and that defective cellular immunity was probably not the reason that
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challenge.
To gain greater insight into the mechanisms contributing to the
increased susceptibility of immunized IL-10 deﬁcient mice versus
immunized wild-type mice to challenge with cowpox virus, we
repeated the challenge experiment, and in addition took samples to
assay for potential differences in adaptive immune responses, lung
pathology, or virus titers between wild-type and IL-10 deﬁcient mice
after secondary challenge.
As shown in Fig. 6A, when mice were primed with 103 PFU
of cowpox virus, and rechallenged 10 weeks later with a lethal dose
(106 PFU) of cowpox virus, therewas a signiﬁcant difference inweight
loss and survival between wild-type and IL-10 deﬁcient animals. As in
the ﬁrst study, wild-type mice were immune to secondary challenge,
and all animals survived. The majority of the IL-10 deﬁcient mice
however succumbed to disease by the seventh day after secondary
challenge. All naive mice (wild-type and IL-10 deﬁcient mice) rapidly
succumbed to infection with a lethal dose (106 PFU) of CPXV (Fig. 6B).
One possibility that could explain the difference in resistance to
secondary challenge was that adaptive immune responses capable of
clearing the virus (neutralizing antibody and CD8 T cells) might bedeﬁcient in the IL-10 deﬁcient mice. Consistent with this idea, the
post-challenge antibody titers (Fig. 6C), and the expansion of CD8 T
cells (Fig. 6D) in the IL-10 deﬁcient mice were lower than those in
wild-type mice. Accordingly, viral replication may not have been as
well controlled in the IL-10 deﬁcient animals as in wild-type mice.
Consistent with this possibility, at 3 and 6 days after rechallenge, viral
loads in the lungs of infected IL-10 deﬁcient mice were slightly higher
than those of wild-type mice (Fig. 6E). Perhaps more importantly,
while viral loads of wild-typemice declined from day 3 to day 6, those
of IL-10 deﬁcient animals increased.
An additional possibility was that a vigorous inﬂammatory
response may have contributed to pulmonary pathology in the IL-10
deﬁcient mice. To test this possibility, pathology in the lungs of wild-
type and IL-10 deﬁcient mice was scored according to four criteria as
shown in Fig. 7). In naive mice challenged with 106 PFU of cowpox
virus, both wild-type and IL-10 deﬁcient mice showed a similar
pattern of pathology, with extensive ﬁbrinohemorrhagic necrosis
around the pulmonary arteries and their segmental branches.
Notably, there was no evidence of lymphocyte inﬁltration in the
naive mice challenged with CPXV, which is consistent with previous
reports describing a deﬁcient primary response to poxviruses. In mice
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92 A.H. Spesock et al. / Virology 417 (2011) 87–97rechallenged with cowpox virus, pathology was signiﬁcantly differ-
ent, with the most dominant ﬁnding in both wild-type and IL-10
deﬁcient mice being a marked perivascular lymphocytic inﬁltrate.
Both wild-type and IL-10 deﬁcient mice also demonstrated marked
bronchiolitis and bronchopneumonia during secondary challenge.
Importantly however, IL-10 deﬁcient mice had a much higher degree
of bronchopneumonia than wild-type animals at both timepoints
tested (Fig. 7).
Discussion
The results of this study show that cowpox virus, which unlike a
number of viruses, such as orf virus, lacks the capacity to encode a
viral homologue of IL-10, can induce host cell IL-10 both in vitro and
in vivo. In addition, both in vitro and in vivo, at similar doses or at
similar viral loads, cowpox virus has greater capacity than vaccinia
virus to induce IL-10, suggesting that the induction of IL-10 is not
simply a non-speciﬁc host response to orthopoxviral infection, but
that it may reﬂect yet one more way in which cowpox virus controls
immune responses.
A cowpox virus-speciﬁc mechanism of induction of IL-10 would be
in accordance with the results of previous studies suggesting that
cowpox virus could induce greater levels of IL-10 than vaccinia virus
in vivo (Knorr et al., 2006; Smee et al., 2008), as well as the much
greater array of accessory genes present in cowpox virus genome of225-kb (Genbank AF482758) as compared to that of the 195-kb
genome of vaccinia virus WR (Genbank AY243312).
The effects of IL-10 on orthopoxvirus infections, using vaccinia
virus as the model virus, have been the subjects of two earlier studies.
Kurilla et al. (1993) examined the effects of viral-vectored expression
of mouse IL-10 on vaccinia virus infection in mice. They showed that
the effects of this viral expression of IL-10 were subtle, with infections
by a variety of routes (including dermal scariﬁcation, intraperitoneal,
intranasal, and intracerebral routes) resulting in little difference
between control virus and IL-10-expressing VV as judged by visible
lesions, mortality, antibody response, or protection against subse-
quent challenge with a 100-fold lethal dose of VV. In immunocom-
petent mice, they noted that the recombinant vaccinia virus
expressing IL-10 induced less natural killer (NK) cell and VV-speciﬁc
cytotoxic T-cell activities than control virus. Consistent with these
studies van Den Broek et al. (2000) showed that after intraperitoneal
infection, IL-10 deﬁcientmice cleared vaccinia virusmore rapidly than
wild-type mice. Together, these two studies suggested that IL-10
could have the effect of suppressing host defenses against vaccinia
virus.
In this study, after intranasal infections with cowpox virus, we
detected no signiﬁcant differences between IL-10 deﬁcient mice and
wild-typemicewith respect to any of the following:weight loss; clinical
signs; temperature; viral load in the lungs; antibody or cellular immune
responses to viral proteins. Poxviruses are cleared from the host by the
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93A.H. Spesock et al. / Virology 417 (2011) 87–97combined action of neutralizing antibody and cellular responses
involving cytotoxic T lymphocytes, and NK cells (Chaudhri et al., 2006,
2009; Panchanathan et al., 2006; Xu et al., 2004). Presumably, in the
vaccinia model, cellular responses were augmented in the absence of
IL-10, because IL-10 has potent immunosuppressive activity. In our
cowpox virus model, there was no apparent increase in the activity of
cellular antiviral responses in IL-10 deﬁcient mice. This result could
mean that the effects of IL-10 produced during infection with cowpox
virus infection are less evident than those on vaccinia virus because
cowpox virus encodes many more immunomodulatory proteins than
vaccinia virus. Speciﬁcally, cowpox virus can interferewith both NK and
T cell functions inways that vaccinia virus cannot. For example, cowpox
encodes a high afﬁnity antagonist of the NKG2D, an activating receptorof NK lymphocytes aswell as some CD8 TCR-αβ T cells, splenic TCR-γδT
cells, and murine macrophages (Campbell et al., 2007; Obeidy and
Sharland, 2009), whereas vaccinia virus does not. Also, cowpox virus
encodes two proteins (CPXV12 and CPXV203) that abrogateMHC class I
expression to evade antiviral CD8 T cells (Alzhanova et al., 2009; Byunet
al., 2009, 2007), whereas vaccinia virus does not encode either of these
proteins. Therefore, even though cowpox virus may be able to induce
more IL-10 than vaccinia virus, it may nonetheless be much more
competent than vaccinia virus at suppressing immune responses even
in the absence of IL-10.
Surprisingly, IL-10 deﬁcient mice immunized with cowpox virus,
and then challenged with lethal doses of cowpox virus, were not
protected as well as wild-type mice, even though the titers of
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94 A.H. Spesock et al. / Virology 417 (2011) 87–97antibodies against the B5 protein, titers of neutralizing antibodies, and
assays of CD8 T cells recognizing the immunodominant epitope
(TSYKFESV) of the cowpox virus B8 protein, failed to show any
signiﬁcant differences in these parameters between IL-10 deﬁcient
mice and wild-type mice (Fig. 5). However, upon re-infection, the
antibody and CD8+ T-cell responses were lower in IL-10 deﬁcient
mice than wild-type mice, which may have contributed to increased
viral loads in the IL-10 deﬁcient mice. It is also possible that after
challenge, the immunized IL-10 deﬁcient mice may mount a more
robust cytokine response than wild-type mice, leading to an
exacerbation of immunopathological responses, including pro-
nounced weight loss, even in the presence of what would normally
be expected to be protective antibody titers. Previously, IL-10 has
been shown to play a role in suppressing immunopathological
responses to Toxoplasma gondii (Gazzinelli et al., 1996) and
Trypanosoma cruzi (Hunter et al., 1997).
The results of this study comparing cowpox virus infections in
wild-type and IL-10 deﬁcient mice conﬁrm that IL-10 has an
important role in reducing immunopathological effects during
primary and secondary viral infections. Further, they suggest that a
diminished capacity to produce IL-10 may exacerbate reactions to
cowpox virus infections, reinfections, or challenges post-immuniza-
tion. The ability of cowpox virus to induce IL-10 suggests that this
property is advantageous to the virus, but additional studies will be
needed to determine how this property contributes to viral
replication in the natural environment.
Materials and methods
Viruses and cells
Cowpox virus, strain Brighton red, and vaccinia viruses, strains
Western Reserve (WR) and MVA, were prepared by standard methods
(Carroll and Moss, 1997). All viruses were puriﬁed by velocity gradient
centrifugation as previously described (Joklik, 1962). All virus stocks
were tested by culture on chocolate agar, and by PCR screening, to
conﬁrm the absence of contamination with bacteria, including myco-
plasma. Viruses were quantiﬁed by plaque assay on human 143B cells,
BSC-1 cells, or BHK cells as previously described (Lynch et al., 2009).
Bone marrow cells were harvested from 8 to 16-week old femaleC57BL/6NCrl mice (from Charles River Laboratories), and cultured into
BMDCs as described (Inaba et al., 1992; Lee et al., 2005).Reagents
Lyophilized recombinant mouse IL-4 and GM-CSF (R&D Systems,
Minneapolis, MN) were suspended in sterile, distilled water at
10 pg/ml. Trioxsalen (4′-Aminomethyl-Dihydrochloride) was diluted
in sterile, distilled water to 1 mg/ml, and ﬁlter sterilized. Lyophilized
LPS from Escherichia coli 0111:B4 (InVivoGen, San Diego, CA), a TLR4
agonist was reconstituted at 5 mg/ml with sterile endotoxin-free
water, for use at ﬁnal concentration of 1 μg/ml. Lyophilized Pam3CSK4
(InVivoGen), a TLR2/TLR1 agonist, was reconstituted at 1 mg/ml with
sterile endotoxin-free water, for use at ﬁnal concentration of 1 μg/ml.
Lyophilized ODN 1826 (InVivoGen), an unmethylated oligonucleotide
with CpG motifs that stimulates mouse TLR9, was reconstituted at
500 μM in sterile endotoxin-free water, for use at ﬁnal concentration
of 5 μM. Lyophilized recombinant mouse IL-10 (provided with OptEIA
ELISA set, BD Biosciences) was reconstituted with 1 ml sterile,
distilled water to 175 ng/ml. SuperBlock consisted of PBS, pH 7.4
containing 4% BiPro original instant whey protein isolate supplement
(Davisco Food Intl., Eden Prairie, MN), 15% normal goat serum, 0.05%
Tween-20 and 0.05% sodium azide.Inoculation of mice
Eight to 10-week-old female C57BL/6J mice or IL-10 deﬁcient
mice (B6.129P2-Il10tm1Cgn/J) were obtained from Jackson Labora-
tories. Mice were housed in microisolator cages in a biosafety level
2-equipped animal facility, with mice housed for at least 1 week
before experiments were initiated. For intranasal challenge with
viruses, mice were lightly anesthetized with isoﬂurane using a
vaporizer, and each mouse was administered the indicated amount
of virus in 30 μl total volume. The Institutional Animal Care and Use
Committee of Duke University approved all animal experiments.
After challenge mice were monitored daily for weight loss and
change in body temperature (Physitemp rodent thermometer,
Physitemp Inc., Clifton, NJ).
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Murine IL-10 (in cell culture media, serum or the bronchoalveolar
lavage ﬂuid of animals) was quantiﬁed using an OptEIA ELISA set (BD
Biosciences), or Bio-Plex assay (Bio-Rad Laboratories), according to
the manufacturer's instructions. All samples were assayed in
duplicate. Numbers reported are in pg/ml as determined via linear
regression using a standard curve.
Preparation of organs for titration of infectious virus
Mice were euthanized via anesthetic overdose. Immediately after
death, the left atriumwas nicked and lungs were perfused with sterile
PBS through the right ventricle. Lungs were aseptically removed,
weighed, and frozen. To obtain suspensions for titration, lungs were
thawed, and homogenized using a tissue homogenizer in 3× their
volume (0.1 ml PBS for every 100 μg weight). Suspensions were
sonicated, centrifuged to remove solids, aliquoted, and stored at
−80 °C. For titration, samples were thawed, serially diluted, and
assayed on semiconﬂuent BSC-1 cells (CPXV and VV-WR) or BHK cells
(MVA). Plaques were visualized after 48 h by staining with crystal
violet.
Bronchoalveolar lavage and lung parenchymal cell isolation
BAL ﬂuid and lung cells were collected as previously described (Lin
et al., 2008). Brieﬂy, mice were euthanized by isoﬂurane inhalation.
For BAL collection, the trachea was cannulated with an 18-gauge
angiocath connected to a 1 ml syringe, and the lungs ﬂushed with PBS
until a total of 2 ml was collected. BAL ﬂuid was centrifuged and the
supernatant frozen immediately at −80 °C for subsequent assays. To
obtain leukocytes, lungs were perfused with 3 ml of PBS. Lungs were
minced, and incubated for 30–40 min at 37 °C with 5 ml HBSS
containing 5% FBS, 10 mM HEPES, 1 mg/ml collagenase (crude, type
1A) and 0.2 mg/ml DNAse I (from bovine pancreas, Sigma). The
collagenase digestionwas stoppedwith 1 ml cold 120 mMEDTA. Cells
were dissociated through a 70 μm mesh strainer and centrifuged at
220×g for 20 min over an 18.23% Nycodenz cushion. Low-density
cells were collected, diluted in HBSS with 5% FBS, 10 mM EDTA and
10 mMHEPES (HBSS-5), centrifuged, and suspended in red blood-cell
lysing media (Sigma) for 5 min. Cells were washed, and resuspended
with HBSS-5, then passed through a 35 μm mesh strainer to remove
DNA aggregates. Cells were centrifuged, and resuspended in HBSS-5,
then counted and stained for ﬂow cytometry.
Flow cytometry
All antibodies were used at the staining saturation point. Cell
surface staining was performed as previously described (Lin et al.,
2008). Lung cells were washed twice with ﬂow buffer (HBSS
supplemented with 5% FBS and 10 mM EDTA), then resuspended in
ﬂow buffer containing 5% normal mouse serum, 5% normal rat serum
(Jackson ImmunoResearch), and 1% rat IgG2b,κ anti-CD16/CD32 (BD
Biosciences). The cells were incubated on ice for at least 10 min, then
antibodies were added, and the cells incubated for at least 20 min.
Cells were washed twice with ﬂow buffer. Cells were resuspended in
ﬂow buffer, and phenotyped on a FASCS Aria or LSR II ﬂow cytometer
(BD Biosciences). Unstained cells and cells stained with each antibody
were used to compensate the data. The data were analyzed using
FlowJo software (Tree Star). Cells were gated on FSC-A/FSC-H to
removed doublets, and FSC-A/SSC-A to remove debris (data not
shown). The following antibodies were used to stain cells: rat IgG2a,κ
anti-mouse I-A/I-E-FITC, rat IgG2a,κ anti-mouse Ly6G-PE, rat IgG2b,κ
anti-mouse Gr-1-APC, rat IgG2b,κ anti-mouse CD11b-APC-Cy7, mouse
IgG2a,κ anti-mouse NK1.1-FITC, rat IgG2b,κ anti-mouse CD4-PE (BD
Biosciences), rat IgG2a,κ anti-mouse CD19-PE-Cy5.5 (Biolegend), ratIgG2a,κ anti-mouse CD8α-APC and Armenian hamster IgG anti-mouse
CD11c-PE-Cy5.5 (eBioscience).
ELISA for binding antibody
The ectodomain (amino acids 1–279) of the B5 protein of CPXV,
was expressed, puriﬁed, and used to assay for binding antibody as
described (Barefoot et al., 2008). Brieﬂy, 96-well Immulon II ELISA
plates (Fisher) were coated with puriﬁed B5 protein (200 ng per well)
in bicarbonate buffer (0.1 M NaHCO3) overnight at 4 °C. Wells were
washed, blocked with Superblock (15% normal goat serum, 0.04%
whey in PBS-Tween), and incubated with diluted sera. Antibody was
detected with alkaline-phosphatase conjugated goat anti-mouse Ig,
and antibody reactivity was detected by adding pNPP substrate (4-
nitrophenyl phosphate Sigma N2640) at 1 mg/ml as directed by the
manufacturer, incubating for 45 min, and reading Abs at 405 nm.
Serum Ig endpoint titers are reported as the reciprocal of the highest
dilution that gave absorbance greater than 2-fold over background,
where background is the absorbance for pre-immune serum at the
same dilution. Sera from the animals were assayed individually, and
compared to individual pre-immune titers. Buffer alone was included
as a negative control, and serumwith a known endpoint dilution of B5
was used as a positive control for the assay.
Plaque reduction neutralization assays were conducted as de-
scribed (Law and Smith, 2001) to measure serum neutralizing
activities against cowpox virus mature virions.
Tetramer assay
Splenocytes were obtained by disrupting spleens between the
frosted ends of two microscope slides. Red blood-cells were removed
using red blood-cell lysing buffer (Sigma). Cells were washed and
resuspended for staining. Brieﬂy, 5×106 cells were added to the
bottom of a V-bottom plate, and blocked with unconjugated
streptavidin (Molecular Probes), and FcBlock (Pharmingen) for
15 min at room temperature. Cells were then labeled with FITC-
conjugated anti-CD62L, APC-conjugated anti-CD8, and a PE-conjugat-
ed tetramer. The tetramer was anMHC class I Kb tetramer recognizing
the immunodominant Kb-restricted B8 epitope of vaccinia virus (N-
TSYKFESV-C) as described (Tscharke et al., 2005). The tetramer was
obtained from the NIH Tetramer Facility.
Histopathologic scoring
Lungs were harvested as described above and were submitted to
the Duke Pathology Research Laboratory for tissue processing,
embedding, sectioning, and staining with hematoxylin and eosin per
standard diagnostic protocols. Six levels of tissue sections were taken
from each lung. Each histopathologic endpoint was scored on a scale
of 0–4 using standard criteria as follows. All slides were coded and
scored “blinded.” Periarterial ﬁbrinohemorrhagic degeneration was
seen only in the naive mice (0=no degeneration; 1=trace
degeneration; 2=mild degeneration; 3=moderate degeneration;
4=severe degeneration). Perivascular lymphocytic inﬁltrates were
seen only in rechallenged mice (0=no inﬁltrates; 1=trace in-
ﬁltrates; 2=mild inﬁltrates; 3=moderate inﬁltrates; 4=marked
inﬁltrates). Bronchiolitis was seen in all animals (0=no bronchiolitis;
1=mild respiratory epithelial edema/hypertrophy; 2=moderate
bronchiolitis with neutrophilic inﬁltrates; 3=severe bronchiolitis
with neutrophilic inﬁltrates and focal breakdown of the bronchial
wall; 4=severe necrotizing bronchiolitis with obliteration of the
bronchial wall). Bronchopneumonia was seen in all animals (0=no
bronchopneumonia; 1=mild focal bronchopneumonia; 2=moder-
ate bronchopneumonia with clustering and focal conﬂuence across
two bronchioles and associated lobular units; 3=severe broncho-
pneumonia with conﬂuence across three or more bronchioles and
96 A.H. Spesock et al. / Virology 417 (2011) 87–97associated lobular units; 4=severe bronchopneumonia with regional
sublobar or lobar consolidation.Statistical analyses
Numerical data analyses were performed using Prism Software
(GraphPad Software). Data are presented as themean±SEMor points
representing individual animals with mean as indicated in the ﬁgure
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